The following is written by Sheldon S. Sones, RPh, FASCP, President, Sheldon S. Sones and Associates. Monoamine oxidase inhibitors (MAO inhibitors or MAOIs) are drugs which, by virtue of their ...

Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively ...

Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack ...

As well as causing considerable pain, rheumatoid arthritis (RA) can also trigger neuropsychiatric problems including memory impairment. Scientists have now examined the role of monoamine oxidase-B ...

A class of antidepressants known as monoamine oxidase inhibitors (MAOIs) first hit the market in the 1950s and has since been eclipsed by drugs that are less likely to cause unwanted side effects. Now ...

Monoamine oxidase inhibitors (MAOIs) have a long and prosperous history as medications for major depressive disorder (MDD). But this type of antidepressant has mostly seen its day. Though MAOIs are ...

Miralogx LLC and Mira Pharmaceuticals Inc. have jointly disclosed new cannabinoid analogues acting as monoamine oxidase-A (MAO-A) and/or MAO-B inhibitors reported to be useful for the treatment of ...

In the years after World War II, there were no effective medicines for schizophrenia, bipolar disorder, or major depression. There were not even names for such things. The word ‘antipsychotic’ was ...

Rheumatoid arthritis (RA) is an autoimmune disease that causes extensive inflammation of the joints, causing severe pain and discomfort in patients. But did you know that the disease is also commonly ...